Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Neuraxpharm and Panaxia Partner For Poland, After Germany And France

Companies Expect Sale Of Medical Cannabis-Based Product To Commence in First Half Of 2022

Executive Summary

CNS specialist Neuraxpharm has announced expanding its strategic collaboration with Panaxia Labs Israel for advanced medical cannabis-based pharmaceutical products to Poland, after Germany and France. The companies expect sale of the cannabis portfolio to commence in the first half of 2022.

 

You may also be interested in...



Panaxia And Neuraxpharm Sign To Sell Medical Cannabis In The Czech Republic And Switzerland

Panaxia and Neuraxpharm have added the Czech Republic and Switzerland to their growing list of European markets for medical cannabis. Both countries have passed recent legislation to stimulate prescriptions of cannabis products.

Neuraxpharm Boosts Branded Business With Established Sanofi Portfolios

CNS specialist Neuraxpharm has purchased two of Sanofi’s product portfolios, substantially expanding the number of branded products it has to offer.

Neuraxpharm And Panaxia Take Cannabis Tablets To France

Neuraxpharm and Panaxia have continued to push forward with their partnership on medical cannabis, exporting sublingual tablets to France as part of a pilot program organized by local regulator ANSM.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151195

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel